Nicole Ocasio-Martinez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nicole Ocasio-Martinez has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Charles G. Mullighan
St Jude Children's Research Hospital, Memphis, Tennessee, United States
2 shared publications - Kimberly Stegmaier
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, USA
2 shared publications A Herman
Broad Institute of Harvard and MIT, Cambridge, MA
1 shared publicationA Robichaud
Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children’s Hospital; Harvard Medical School, Boston, MA
1 shared publication- Adam David Durbin
Division of Molecular Oncology, Department of Oncology, St. Jude Children’s Research Hospital, Memphis, USA
1 shared publication - Alexander Viloria Winnett
California Institute of Technology
1 shared publication
Latest Publications
- Open Access
- 2 October 2026
- Published by Taylor & Francis in Behavioral Medicine
- Vol. 52 (3-4) , 348-361
Community-Based Accompaniment for Adolescents and Young Adults Transitioning into Adult HIV Care: Protocol of a Randomized Control Trial Evaluating the “PASEO” Intervention in Urban Peru
Living with HIV in adolescence and young adulthood further complicates a challenging life stage. At a time when the desire for peer acceptance is heightened, HIV-related stigma and isolation can ex...
- 2 October 2026
- Published by Taylor & Francis in Behavioral Medicine
- Vol. 52 (3-4) , 348-361
Open AccessCommunity-Based Accompaniment for Adolescents and Young Adults Transitioning into Adult HIV Care: Protocol of a Randomized Control Trial Evaluating the “PASEO” Intervention in Urban Peru
Living with HIV in adolescence and young adulthood further complicates a challenging life stage. At a time when the desire for peer acceptance is heightened, HIV-related stigma and isolation can ex...
- Open Access
Tabular foundation model predicts alternative lengthening of telomeres (ALT) and identifies SMARCAL1 as a target in ALT-driven cancers
Alternative lengthening of telomeres (ALT) is a telomerase-independent pathway used by aggressive cancers to maintain their replicative immortality. Because ALT is absent from normal human cells, it is an appealing target for cancer therapy, but the lack of ability to determine ALT status at scale has hindered discovery. Here, we developed ALTitude, a machine learning method from a tabular foundation model that infers ALT from cell line whole genome sequencing data, without need for paired germline analysis. We deployed ALTitude across the DepMap, doubling the number of known ALT+ cancer models. Systematic integration of ALTitude with CRISPR-Cas9 screens yielded the selective dependency on SMARCAL1 in ALT+ cell lines, where we show it stabilizes the ALT phenotype. Acute depletion of SMARCAL1 leads to G2/M arrest, mitotic catastrophe, and cell death. These data provide a valuable resource for studying ALT-related genomic features and present SMARCAL1 as a therapeutic target for ALT+ malignancies.
Open AccessTabular foundation model predicts alternative lengthening of telomeres (ALT) and identifies SMARCAL1 as a target in ALT-driven cancers
Alternative lengthening of telomeres (ALT) is a telomerase-independent pathway used by aggressive cancers to maintain their replicative immortality. Because ALT is absent from normal human cells, it is an appealing target for cancer therapy, but the lack of ability to determine ALT status at scale has hindered discovery. Here, we developed ALTitude, a machine learning method from a tabular foundation model that infers ALT from cell line whole genome sequencing data, without need for paired germline analysis. We deployed ALTitude across the DepMap, doubling the number of known ALT+ cancer models. Systematic integration of ALTitude with CRISPR-Cas9 screens yielded the selective dependency on SMARCAL1 in ALT+ cell lines, where we show it stabilizes the ALT phenotype. Acute depletion of SMARCAL1 leads to G2/M arrest, mitotic catastrophe, and cell death. These data provide a valuable resource for studying ALT-related genomic features and present SMARCAL1 as a therapeutic target for ALT+ malignancies.
- Open Access
- 5 August 2025
- Published by MIT Science Policy Review
- Vol. 6, 36-59
A decennial review of health disparities among the growing Bi+ population in the United States
Nearly 14 million individuals in the United States (U.S.) currently identify as Bi+ (bisexual, pansexual and other terms), and this segment of the population–5.2% of adults–is growing each year. Yet, marginalization by monosexual (i.e., heterosexual and homosexual) communities has resulted in significant health disparities for Bi+ populations. With a focus on research that has emerged in the past decade, this review describes current conceptualizations of the mechanisms underlying Bi+ health disparities and available high-quality evidence for Bi+ health disparities related to healthcare access, mental health, diagnosis and prevention of HIV and Mpox virus, and other physical health conditions. As the Bi+ population includes substantial racial/ethnic and gender diversity, we discuss the intersection and nuanced effect of these demographic factors on Bi+ health disparities. Findings from this decennial Review reveal challenges and opportunities for policies to reduce health disparities among the rapidly growing Bi+ population in the U.S.
- 5 August 2025
- Published by MIT Science Policy Review
- Vol. 6, 36-59
Open AccessA decennial review of health disparities among the growing Bi+ population in the United States
Nearly 14 million individuals in the United States (U.S.) currently identify as Bi+ (bisexual, pansexual and other terms), and this segment of the population–5.2% of adults–is growing each year. Yet, marginalization by monosexual (i.e., heterosexual and homosexual) communities has resulted in significant health disparities for Bi+ populations. With a focus on research that has emerged in the past decade, this review describes current conceptualizations of the mechanisms underlying Bi+ health disparities and available high-quality evidence for Bi+ health disparities related to healthcare access, mental health, diagnosis and prevention of HIV and Mpox virus, and other physical health conditions. As the Bi+ population includes substantial racial/ethnic and gender diversity, we discuss the intersection and nuanced effect of these demographic factors on Bi+ health disparities. Findings from this decennial Review reveal challenges and opportunities for policies to reduce health disparities among the rapidly growing Bi+ population in the U.S.
- 19 September 2023
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (22) , 4613-4626
Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Purpose: Patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (T-LBL) have limited therapeutic options. Clinical use of genomic profiling provides an opportunity to identify targetable alterations to inform therapy. Experimental Design: We describe a cohort of 14 pediatric patients with relapsed or refractory T-ALL enrolled on the Leukemia Precision-based Therapy (LEAP) Consortium trial (NCT02670525) and a patient with T-LBL, discovering alterations in platelet-derived growth factor receptor-α (PDGFRA) in 3 of these patients. We identified a novel mutation in PDGFRA, p.D842N, and used an integrated structural modeling and molecular biology approach to characterize mutations at D842 to guide therapeutic targeting. We conducted a preclinical study of avapritinib in a mouse patient-derived xenograft (PDX) model of FIP1L1-PDGFRA and PDGFRA p.D842N leukemia. Results: Two patients with T-ALL in the LEAP cohort (14%) had targetable genomic alterations affecting PDGFRA, a FIP1-like 1 protein/PDGFRA (FIP1L1-PDGFRA) fusion and a novel mutation in PDGFRA, p.D842N. The D842N mutation resulted in PDGFRA activation and sensitivity to tested PDGFRA inhibitors. In a T-ALL PDX model, avapritinib treatment led to decreased leukemia burden, significantly prolonged survival, and even cured a subset of mice. Avapritinib treatment was well tolerated and yielded clinical benefit in a patient with refractory T-ALL. Conclusions: Refractory T-ALL has not been fully characterized. Alterations in PDGFRA or other targetable kinases may inform therapy for patients with refractory T-ALL who otherwise have limited treatment options. Clinical genomic profiling, in real time, is needed for fully informed therapeutic decision making.
- 19 September 2023
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (22) , 4613-4626
Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Purpose: Patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (T-LBL) have limited therapeutic options. Clinical use of genomic profiling provides an opportunity to identify targetable alterations to inform therapy. Experimental Design: We describe a cohort of 14 pediatric patients with relapsed or refractory T-ALL enrolled on the Leukemia Precision-based Therapy (LEAP) Consortium trial (NCT02670525) and a patient with T-LBL, discovering alterations in platelet-derived growth factor receptor-α (PDGFRA) in 3 of these patients. We identified a novel mutation in PDGFRA, p.D842N, and used an integrated structural modeling and molecular biology approach to characterize mutations at D842 to guide therapeutic targeting. We conducted a preclinical study of avapritinib in a mouse patient-derived xenograft (PDX) model of FIP1L1-PDGFRA and PDGFRA p.D842N leukemia. Results: Two patients with T-ALL in the LEAP cohort (14%) had targetable genomic alterations affecting PDGFRA, a FIP1-like 1 protein/PDGFRA (FIP1L1-PDGFRA) fusion and a novel mutation in PDGFRA, p.D842N. The D842N mutation resulted in PDGFRA activation and sensitivity to tested PDGFRA inhibitors. In a T-ALL PDX model, avapritinib treatment led to decreased leukemia burden, significantly prolonged survival, and even cured a subset of mice. Avapritinib treatment was well tolerated and yielded clinical benefit in a patient with refractory T-ALL. Conclusions: Refractory T-ALL has not been fully characterized. Alterations in PDGFRA or other targetable kinases may inform therapy for patients with refractory T-ALL who otherwise have limited treatment options. Clinical genomic profiling, in real time, is needed for fully informed therapeutic decision making.